Dr Geoff Oxnard outlines promising results from the key studies from 2020 on the neoadjuvant or adjuvant treatment of resectable and/or nonmetastatic NSCLC, as well as the value of stereotactic body radiotherapy in place of surgery during the COVID-19 pandemic.
Related Items
JHOP - Supplements published on July 21, 2022 in Lung Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer